{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:24:20Z","timestamp":1787761460880,"version":"build-2784847793"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamadermatol.2020.3257","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:02:39Z","timestamp":1601499759000},"page":"43","source":"Crossref","is-referenced-by-count":71,"title":["Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis"],"prefix":"10.1001","volume":"157","author":[{"given":"Boni E.","family":"Elewski","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Department of Dermatology, Eye Foundation Hospital, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Baddley","sequence":"additional","affiliation":[{"name":"Department of Medicine and Infectious Diseases, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul A.","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Rich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[{"name":"Secci\u00f3n Reumatolog\u00eda, Servicio de Cl\u00ednica M\u00e9dica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Southern California Dermatology and Harbor UCLA (University of California, Los Angeles), Santa Ana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Keininger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwaku","family":"Marfo","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmath","family":"Patekar","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt Ltd, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Shete","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Gabriel","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"doi200052r2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: opportunities and challenges.","volume":"23","author":"Chee","year":"2018","journal-title":"Respirology"},{"issue":"10","key":"doi200052r3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"doi200052r4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","article-title":"Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review.","volume":"20","author":"Snast","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"doi200052r5","first-page":"2077","article-title":"AB1231?Incidence of tuberculosis with rheumatic diseases using TNF inhibitors: a systematic review.","volume":"78","author":"Sartori","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"doi200052r6","first-page":"413","article-title":"Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy.","volume":"24","author":"Valesini","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"doi200052r7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0029-1214673","article-title":"[Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].","volume":"63","author":"Diel","year":"2009","journal-title":"Pneumologie"},{"issue":"5","key":"doi200052r8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"issue":"8","key":"doi200052r9","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3899\/jrheum.120165","article-title":"Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.","volume":"39","author":"Bombardier","year":"2012","journal-title":"J Rheumatol"},{"issue":"10","key":"doi200052r10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","journal-title":"Thorax"},{"issue":"5","key":"doi200052r11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi200052r12","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.","volume":"6","author":"Kamm\u00fcller","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"doi200052r13","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics.","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"4","key":"doi200052r14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"doi200052r15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE).","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi200052r16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi200052r17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE).","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi200052r18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial.","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi200052r19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi200052r20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaad.2019.04.045","article-title":"Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study.","volume":"81","author":"Tha\u00e7i","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"doi200052r22","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16632","article-title":"Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.","author":"Augustin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"doi200052r23","article-title":"Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study.","author":"Mrowietz","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi200052r24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200052r25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi200052r26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/1346-8138.13911","article-title":"Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: a prospective study to evaluate direct switch.","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"J Dermatol"},{"issue":"5","key":"doi200052r27","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks.","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"12","key":"doi200052r28","first-page":"1085","article-title":"Quality of life in psoriasis vulgaris: use of the ItchyQoL questionnaire in a secukinumab phase III trial in patients with psoriasis vulgaris.","volume":"99","author":"St\u00e4nder","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"doi200052r29","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200052r30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"doi200052r31","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16893","article-title":"Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.","author":"Richard","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi200052r32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"doi200052r33","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"doi200052r34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"doi200052r35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study.","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"6","key":"doi200052r36","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"doi200052r37","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1).","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"doi200052r38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study.","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"doi200052r39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"doi200052r40","first-page":"770","article-title":"Non-radiographic axial spondyloarthritis.","volume":"17","author":"Slobodin","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"doi200052r41","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19169","article-title":"Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender.","author":"Iskandar","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200052r42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi200052r43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-a agents: a review.","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"doi200052r44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-a antagonists: a systematic review and meta-analysis of randomised controlled trials.","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"issue":"15","key":"doi200052r45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"doi200052r46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2007.11.022","article-title":"IL-23 and IL-17 in tuberculosis.","volume":"41","author":"Khader","year":"2008","journal-title":"Cytokine"},{"issue":"2","key":"doi200052r47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available.","volume":"175","author":"Khader","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"doi200052r48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections.","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"doi200052r49","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review.","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi200052r50","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10067-013-2387-z","article-title":"Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area.","volume":"33","author":"Kim","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"doi200052r51","article-title":"Challenges in the diagnosis and management of spinal tuberculosis: case series.","volume":"11","author":"Dean","year":"2019","journal-title":"Cureus"},{"issue":"4","key":"doi200052r52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/1117-1936.181413","article-title":"Pulmonary manifestations of ankylosing spondylitis treated as pulmonary tuberculosis: a case report and review of literature.","volume":"16","author":"Ibinaiye","year":"2009","journal-title":"Niger Postgrad Med J"},{"issue":"1","key":"doi200052r53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0007-0971(74)90009-6","article-title":"Pulmonary fibrosis, pulmonary tuberculosis and ankylosing spondylitis.","volume":"68","author":"Crompton","year":"1974","journal-title":"Br J Dis Chest"},{"key":"doi200052r54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000501989","article-title":"Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis.","volume":"11","author":"Ribero","year":"2019","journal-title":"Case Rep Dermatol"},{"issue":"11","key":"doi200052r55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1101\/cshperspect.a017830","article-title":"Diagnosis and management of latent tuberculosis infection.","volume":"5","author":"Mu\u00f1oz","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"doi200052r56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.dsi.2014.12.005","article-title":"Serial QuantiFERON-TB Gold in-tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy.","volume":"33","author":"Cheng","year":"2015","journal-title":"Dermatologica Sin"},{"issue":"9","key":"doi200052r57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184178","article-title":"Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.","volume":"12","author":"Hsiao","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"doi200052r58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225112","article-title":"The seroconversion rate of QuantiFERON-TB Gold in-tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.","volume":"14","author":"Wu","year":"2019","journal-title":"PLoS One"},{"key":"doi200052r1","volume-title":"Global Tuberculosis Report 2019","author":"World Health Organization","year":"2019"},{"key":"doi200052r21","unstructured":"Study of secukinumab with 2 mL pre-filled syringes (ALLURE). ClinicalTrials.gov identifier: NCT02748863. Updated July 15, 2019. Accessed August 28, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02748863"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2771083\/jamadermatology_elewski_2020_oi_200052_1610466927.18173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T19:35:51Z","timestamp":1696793751000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2771083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}